Women's Attitudes and Behaviors towards Vulvar and Vaginal Atrophy (VVA)

Sheryl Kingsberg, PhD¹, Julia Amadio², and Shelli Graham, PhD²

¹University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH and ²TherapeuticsMD, Boca Raton, FL





Disclosures

- S. Kingsberg consultant for TherapeuticsMD, NovoNordisk, Pfizer, Shionogi, Materna, Strategic Science and Technology, Palatin, Sprout, Emotional Brain, Teva
- J. Amadio and S. Graham Employees of TherapeuticsMD

Introduction

- VVA, a component of genitourinary syndrome of menopause (GSM)¹, is prevalent and bothersome in postmenopausal women.
- Recent estimates suggest that up to 32 million women may be experiencing symptomatic VVA.²
 - Dyspareunia and vaginal dryness most common symptoms
- Chronic condition with symptoms worsening over time.
- May negatively affect sexual function, interpersonal relationships, selfesteem, and overall quality of life.³⁻⁵
 - 1. Portman DJ, Gass ML. *Menopause*. 2014;21:1063-1068.
 - Kingsberg SA et al. J Sex Med. 2013;10:1790-1799.
 - 3. Simon et al. *Menopause*. 2013;20:1043-1048.
 - 4. Santoro N, Komi J. *J Sex Med.* 2009;6:2133-2142.
 - 5. Nappi RE et al. *Maturitas*. 2013;75:373-379.

Introduction, cont.

- Despite the ubiquity of symptoms and their detrimental effects, most women fail to get treatment (~ 93%)¹ due to:
 - Fmbarrassment²
 - Lack of knowledge about VVA¹
 - Lack of knowledge of approved treatment options¹
 - Negative attitudes regarding hormone therapy³
- Women who do seek treatment are often dissatisfied with the safety, convenience, and efficacy of current approved products.¹

- . Kingsberg SA et al. J Sex Med. 2013;10:1790-1799.
- Nappi et al. Maturitas. 2010;67:233-238.
- 3. Simon et al. *Menopause*. 2013;20:1043-1048.

Objectives

- To identify women's perceptions of VVA.
- To improve understanding of the reasons why women do or do not take prescription (Rx) therapies for VVA

Methods

- Six in-person focus groups of 38 postmenopausal women diagnosed with VVA and experiencing moderate to severe dyspareunia
- Held in Tampa, Philadelphia, and Chicago from February to March, 2015
- Included both current Rx users and non-users
 - 1 current Rx user group (n=6)
 - 2 mixed groups (n=12)
 - 3 Rx non-user groups (n=20)


Methods, continued

- Facilitated discussion topics included:
 - General health and medical history
 - Menopause experience
 - VVA awareness and knowledge
 - VVA symptoms and HCP diagnosis (yes/no)
 - Impact of dyspareunia (physical, emotional, quality of life)
 - Treatment experience (Rx and/or OTC)
 - Barriers to treatment
 - Risk/benefit of current Rx therapies

Results

Age of Participants

Mean age = 63 (range 49-74)



Demographics

Ethnicity

•	Caucasian	84%
•	African American	8%

• Hispanic 4%

• Other 4%

Education

•	High school / technical school	12%
•	Some college	36%

College graduate 44%

Graduate degree
8%

Women's Comments on Dyspareunia

- Pain is excruciating
 - "Felt like someone was stabbing me with a knife. I could not breathe."
 - "Way more than bothersome ... this is severe pain, this is defeating, this is life changing, this has no end in sight."
 - "It's sharp ... on a 10-point scale, a 10."
 - "Tried to explain it to my husband ... imagine someone with a baseball bat ramming it into you."
- Sensitivity and Pain can be Enduring and Impact Lifestyle
 - "Soreness lasts days afterward."
 - "I used to think menopause was just for a couple of years ... now I know it's forever."
 - "Unable to exercise, uncomfortable jogging or riding a bicycle."
 - "Can't get down on floor and play with grandkids."

Pain Leads to Loss of Sexual Function

- Spontaneity and Pleasure are Gone
- The Experience of Sex Itself is Frustrating
- Intercourse is Much Less Frequent
- Sex and Intimacy are Shut Out of Relationships

Emotional Pain, Low Self-Esteem, and Damaged Relationships are the Consequences

- Participants consistently reported both physical and emotional pain as a result of VVA
 - "The pain is a 7 on the physical side ... a 10 on the emotional side."
- Generalized sadness and guilt are common
- Self-esteem and relationships

Suffering in Silence

- Women felt that the pain and loss of sex was not a topic for "polite conversation"
- Too personal, embarrassing, sensitive, and threatening
- "Contradictory" positions of young, strong, independent women directly against age and the fears of being old, dependent, and sick
- Women turn to complacency and an uncomfortable silence
- Rationalization helps with coping

Discussion with HCP

- Most HCPs did not initiate the discussion
- Many women use "dryness" as a polite way of admitting to sexual problems with their partner but use "pain" as the symptom to be treated
- Often met with less than sensitive response
- Term "atrophy" is used not something patient wants to hear or even think about
 - "I had to look it up in the dictionary ... it means "withering or wasting away."
 - "Doctor said it was a common problem ... just getting old."
- Women were unaware of "dyspareunia" and had little knowledge of how pain related to vaginal changes

Treatment Issues

- Women felt that Few Treatment Options were Discussed with Them
- Over the Counter (OTC) Products
 - Helped with milder symptoms
 - Different with moderate to severe pain
 - Many women still try new OTC products regardless of previous failures
- Barriers to Rx Treatment
 - Lack of knowledge of current products (ie, local vs systemic)
 - Fear of estrogen
 - Treatment characteristics (cost, lack of spontaneity, messy/inconvenient, involves pain or injury with an applicator)

Attitudes to Treatment are Very Different Between Users and Non-Users

Rx Users

- Recognize physical and emotional benefits of estrogen
- Strong anti-aging beliefs (fight to stay young; reverse aging)
- Search out medical advice (switch doctors; demand Rx)
- Empowered personality
- Optimistic and sexually active

Rx Non-Users

- Accept aging and symptoms as inevitable
- Less likely to talk with doctor, embarrassed
- Lack of knowledge, fears and confusion dominate thinking
- Depressed about the future
- Not in an active sexual relationship

Conclusions

- Women tend to think of VVA (Dyspareunia) as a sexual issue and not a general health condition to be discussed with their Gyn, NP or PCP
 - When asked about medical history, women did not mention dyspareunia even those taking Rx treatments
- There is a large, highly motivated patient population demanding solutions to the problem of postmenopausal dyspareunia
- Most women do not currently treat with a prescription product
 - They use ineffective OTC's or no treatment at all
- Consequences of not treating are impactful. Women suffer from:
 - Significant pain
 - Loss of sexual function
 - Emotional trauma
 - Lower self-esteem
 - Damage to marital and partner relationships

Conclusions, cont.

- Women's reactions to estrogen are both a barrier and an opportunity
 - Lack of understanding and generalized fear of estrogen
 - Also seen as a solution to the problem if safety fears can be overcome
- Many of the barriers to treatment can be overcome with education, patient support, and more open discussion of benefit/risk of current treatment options